LNSR

Investigations into Shareholder Rights: Brodsky & Smith is conducting investigations regarding potential breaches of fiduciary duties by the boards of several companies, including LENSAR, 180 Degree Capital, Dun & Bradstreet, and Global Blue, concerning their merger agreements and whether shareholders are receiving fair value for their shares.

Merger Agreements Overview: The article outlines specific merger agreements for each company, detailing the cash offers per share and additional contingent rights or preferred shares involved in the transactions, while raising concerns about the fairness of these processes for shareholders.

Investigation of Companies: Halper Sadeh LLC is investigating several companies, including LENSAR, 180 Degree Capital Corp., Dun & Bradstreet Holdings, and Global Blue Group, for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their recent sales and mergers.

Legal Support for Shareholders: The law firm offers free consultations to affected shareholders regarding their legal rights and options, emphasizing that they operate on a contingent fee basis, meaning no upfront costs for legal fees or expenses.

Investigation Announcements: Brodsky & Smith is reminding investors of ongoing investigations into several companies, including LENSAR, 180 Degree Capital Corp., Dun & Bradstreet, and Global Blue Group, regarding potential breaches of fiduciary duties by their boards during merger agreements.

Merger Details: Each company mentioned has specific terms for acquisition, with cash offers per share and additional conditions, raising concerns about whether shareholders are receiving fair value for their shares.

Investigation of Companies: Halper Sadeh LLC is investigating AZEK Company Inc., LENSAR, Inc., and Dun & Bradstreet Holdings, Inc. for potential violations of federal securities laws related to their respective sales to other companies, with a focus on ensuring shareholder rights and options.

Legal Support for Shareholders: The firm offers legal assistance to shareholders of the involved companies at no upfront cost, aiming to secure increased compensation or additional disclosures regarding the transactions.

Investigation of Companies: Halper Sadeh LLC is investigating AZEK Company Inc., LENSAR, Inc., and Dun & Bradstreet Holdings, Inc. for potential violations of federal securities laws related to their sales to other companies, with a focus on ensuring fair treatment for shareholders.

Legal Support for Shareholders: The firm offers free consultations to affected shareholders regarding their rights and options, emphasizing that they will handle cases on a contingent fee basis, meaning no upfront legal fees are required.

Alcon's Acquisition of LENSAR: Alcon AG is acquiring LENSAR Inc for $14.00 per share, totaling approximately $356 million, with potential additional payments based on future performance, bringing the total deal value to around $430 million. The acquisition aims to enhance Alcon's offerings in femtosecond laser-assisted cataract surgery.

Market Impact and Future Plans: Following the announcement, Alcon's stock rose by 1.91%, while LENSAR's stock fell by 2.40%. The transaction is expected to close by mid-to-late 2025, pending necessary approvals, and will integrate LENSAR’s advanced technologies into Alcon's product portfolio.

Investigation of Companies: Halper Sadeh LLC is investigating AZEK Company Inc., LENSAR, Inc., and Dun & Bradstreet Holdings, Inc. for potential violations of federal securities laws related to their respective sales to other companies, with a focus on shareholder rights and options.

Legal Support for Shareholders: The firm offers legal assistance to shareholders seeking increased consideration or disclosures regarding the proposed transactions, operating on a contingent fee basis where clients do not pay upfront legal fees.

Merger Announcement: Alcon, Inc. has entered into a definitive merger agreement to acquire LENSAR, Inc. for $14.00 per share in cash, totaling approximately $356 million, with potential additional payments based on future performance.

Acquisition Details: The deal includes LENSAR's robotic cataract laser system and software, enhancing Alcon's offerings in femtosecond laser-assisted cataract surgery, with total potential consideration reaching up to $430 million.

Acquisition Announcement: Alcon has entered into a definitive merger agreement to acquire LENSAR, including its ALLY Robotic Cataract Laser Treatment System and proprietary software, for approximately $356 million, with potential total consideration of up to $430 million based on performance milestones.

Impact on Cataract Surgery: The acquisition aims to enhance Alcon's portfolio in femtosecond laser-assisted cataract surgery (FLACS), improving surgical efficiency and precision globally, with the transaction expected to close by mid-to-late 2025 pending regulatory approvals.

Merger Agreement: Alcon has entered into a merger agreement to acquire LENSAR for $14.00 per share in cash, totaling approximately $356 million, with potential additional payments based on future performance.

Transaction Details: The deal includes LENSAR's robotic cataract laser technology and is expected to close by mid-to-late 2025, offering a total potential consideration of up to $430 million if certain milestones are met.

Stock Options Granted: LENSAR, Inc. announced that its board granted stock options to two new non-executive employees, allowing them to purchase 1,600 shares at an exercise price of $13.48 each, with a vesting schedule tied to their continued employment.

Company Overview: LENSAR is a medical device company specializing in advanced systems for cataract treatment, including the ALLY Robotic Cataract Laser System™, which integrates AI and proprietary technology to enhance surgical outcomes.

Financial Performance: LENSAR, Inc. reported fourth-quarter 2024 revenue of $16.7 million, exceeding analyst expectations and marking a 38% year-over-year increase, although it recorded a loss of $1.61 per share, which was larger than anticipated.

Growth in Operations: The company placed 31 ALLY Robotic Cataract Laser Systems in Q4, totaling over 80 placements for the year, contributing to a 26% increase in its installed base and a 24% rise in worldwide procedure volumes.

Financial Performance: LENSAR, Inc. reported a 38% increase in fourth-quarter revenue and a 27% increase for the full year 2024 compared to 2023, with total revenue reaching $53.5 million and recurring revenue exceeding $40 million.

Operational Growth: The company placed 31 ALLY Robotic Cataract Laser Systems in Q4 2024, leading to an 86% increase in placements for the year, while also achieving significant growth in procedure volumes and expanding its market share in the U.S. to over 20%.

Stock Options Granted: LENSAR, Inc. announced the granting of stock options for 875 shares to two newly-hired non-executive employees as an employment inducement, with an exercise price of $10.65 per share and a vesting schedule over four years.

Company Overview: LENSAR is a medical device company specializing in advanced systems for cataract treatment, including the ALLY Robotic Cataract Laser System™, which integrates AI and proprietary software to enhance surgical outcomes.

Stock Options Granted: LENSAR, Inc. announced that its board granted stock options to three new non-executive employees, allowing them to purchase 1,650 shares at an exercise price of $8.69 per share, with a vesting schedule tied to their continued employment.

Company Overview: LENSAR is a medical device company specializing in advanced systems for cataract treatment, including the ALLY Robotic Cataract Laser System™, which integrates AI and proprietary software to enhance surgical outcomes.

Company Announcement: LENSAR, Inc. will have CEO Nick Curtis participate in a fireside chat at the BTIG 4th Annual Ophthalmology Day on December 2, 2024, and will also conduct one-on-one meetings with institutional investors.

Product Overview: LENSAR specializes in advanced robotic laser solutions for cataract treatment, featuring their ALLY Robotic Cataract Laser System™, which integrates AI and proprietary software to enhance surgical outcomes and operational efficiency.

Stock Options Granted: LENSAR, Inc. announced that its board granted stock options to two new non-executive employees, allowing them to purchase a total of 650 shares at an exercise price of $5.38 per share, with vesting conditions tied to their continued employment.

Company Overview: LENSAR is a medical device company specializing in advanced systems for cataract treatment, including the ALLY Robotic Cataract Laser System™, which integrates AI and proprietary software to enhance surgical outcomes and operational efficiency.

Milestone Achievement: LENSAR, Inc. has successfully completed over one million cataract procedures using its advanced robotic laser technology, highlighting its commitment to improving surgical outcomes and patient experiences.

Innovative Technology: The company’s ALLY System combines robotic intelligence with surgeon expertise to enhance cataract surgery, aiming to provide operational efficiencies and better clinical results in both operating rooms and in-office settings.

Stock Options Granted: LENSAR, Inc. announced that its board granted stock options to two new non-executive employees, allowing them to purchase 875 shares at an exercise price of $4.40 per share, with a vesting schedule tied to their continued employment.

Company Overview: LENSAR is a medical device company specializing in advanced systems for cataract treatment, including the ALLY Adaptive Cataract Treatment System, which integrates imaging and software technologies to enhance surgical outcomes.

Stock Options Granted: LENSAR, Inc. announced the granting of stock options to three newly-hired non-executive employees, allowing them to purchase a total of 2,425 shares at an exercise price of $4.63 per share, with vesting conditions tied to their continued employment.

Company Overview: LENSAR is a medical device company specializing in advanced systems for cataract treatment, including its ALLY Adaptive Cataract Treatment System, which integrates AI and proprietary software to enhance surgical outcomes and operational efficiency.